Abstract: Objective : To prepare hybrid SK0V3/DC cells by fusing dendritic cells (DC) derived from cord blood and SK0V3 ovarian cancer cells and to analyze anti-tumor immune response to ovari-an cancer cells in vitro. Methods : 1) Using polyethylene glycol (PEG) SK0V3 cells were fused to DC that was then stained with red fluorescent PKH26. The SK0V3/DC fused cells were selected by flow cytometry. 2) Flow cytometry and light microscopy were used to study the morphology of SK0V3/DC in vitro. MTT assay was used to detect the fused cells" ability to activate a mixed lymphocyte reaction. The killing action of the specific anti-tumor immune response was also assessed. Results : 1) The DC were fused with SK0V3 cells at a ratio of 10:1 and the fusion rate was about 8.5%. SK0V3/DC could prolif-erate slowly in vitro and expressed CA125, CD I a, CD80, CD86, HLA-DR, and MHC-I molecules. 2) SKOV3/DC could stimulate a mixed lymphocyte reaction (MLR) efficiently in vitro; SKOV3/DC could activate cytotoxic T lymphocytes that could kill the SKOV3 cells specifically. Conclusion : SKOV3/DC obtained by PEG treatment have some characteristics of both parental cells and were capa-ble of inducing a specific anti-tumor immune response to ovarian cancer cells in vitro. These data sim-ulating an SKOV3/DC vaccine provide evidence for effective immunotherapy against ovarian cancer.